Skip to main content
. 2021 Aug 16;76(10):1775–1783. doi: 10.1093/gerona/glab208

Figure 4.

Figure 4.

Protective effects of recombinant human LAV-BPIFB4 against SARS-CoV-2 lysate-induced cytotoxicity in vitro. Bar graph showing average cytotoxicity (±SD) determined using LDH assay in (A) BEAS-2B (human bronchial epithelial cells), (B) A549 (human alveolar basal epithelial cells), and (C) HUVEC (human umbilical vein endothelial cells) following 3 days treatment with SARS CoV-2 lysate or control lysate (50 μg/mL) in presence or absence of rhLAV-BPIFB4 (18 ng/mL; n = 3). p-values indicate significance levels comparing average lactate dehydrogenase release among different groups (analysis of variance).